文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

尼古丁替代疗法个性化剂量与标准剂量治疗烟草依赖:随机安慰剂对照试验方案

Personalized dosing of nicotine replacement therapy versus standard dosing for the treatment of individuals with tobacco dependence: study protocol for a randomized placebo-controlled trial.
PubMed 文献 · Trials · 2020-06-29

本研究为多中心、实用性、双臂、安慰剂对照、区组随机对照试验,计划招募每日吸烟≥10支且有意戒烟者。经2周21mg尼古丁贴片常规治疗未戒烟者(目标样本量400例)随机接受剂量递增尼古丁贴片(最高84mg/日)或匹配安慰剂贴片额外10周,主要结局为治疗最后4周(第9至12周)生化确认的持续戒烟。

要点

  • 每日吸烟≥10支者经2周21mg贴片未戒烟后,随机比较递增剂量贴片(最高84mg/日)与安慰剂贴片。
  • 主要结局为治疗第9至12周生化确认的持续戒烟。
  • 前2周即戒烟者继续21mg贴片10周,形成额外对照臂。

核心结论

  • 研究将检验尼古丁贴片剂量滴定(最高84mg/日)是否较21mg贴片联合递增安慰剂贴片提高戒烟成功率。

研究设计与样本

  • 多中心、实用性、双臂、安慰剂对照、区组随机对照试验。
  • 招募每日吸烟至少10支且有意尝试戒烟者。
  • 经2周21mg贴片常规治疗未戒烟者(目标n=400)随机分组。
  • 随机后接受递增剂量尼古丁贴片或匹配安慰剂贴片额外10周,最高84mg/日。
  • 前2周即戒烟者继续21mg贴片10周,构成额外对照臂。

关键数值与推荐

  • 随机分组条件:2周21mg贴片常规治疗后未戒烟。
  • 干预剂量:尼古丁贴片递增至最高84mg/日,持续额外10周。
  • 主要结局:治疗最后4周(第9至12周)生化确认的持续戒烟。
  • 所有参与者每次访视接受简短行为咨询。

临床怎么用

  • 若个性化剂量被证实有效,可能改变多种医疗场景中尼古丁替代疗法的现有实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Medications for smoking cessation are currently only effective in helping a minority of smokers quit. Drug development is slow and expensive; as such, there is much interest in optimizing the effectiveness of existing treatments and medications. Current standard doses of nicotine replacement therapy are not effective for many smokers, and in many cases, the amount of nicotine provided is much less than when a smoker is smoking their usual number of cigarettes. The proposed study will test if titrating the dose of the nicotine patch (up to 84 mg) will improve quitting success compared to those receiving a 21-mg nicotine patch with increasing doses of placebo patch. METHODS: This is a multicenter, pragmatic, two-arm, placebo-controlled, block randomized controlled trial. We will recruit participants who smoke at least 10 cigarettes daily and are interested in making a quit attempt. After 2 weeks of usual treatment with a 21-mg patch, participants who fail to quit smoking (target n = 400) will be randomized to receive escalating doses of a nicotine patch vs matching placebo patches for an additional 10 weeks or up to a maximum dose of 84 mg per day. Those who stop smoking during the first 2 weeks of usual treatment will continue with 21 mg patch treatment for 10 weeks and will form an additional comparison arm. In addition to the medication, participants will receive brief behavioral counseling at each study visit. The primary outcome will be biochemically confirmed continuous abstinence from smoking during the last 4 weeks of treatment (weeks 9 to 12). DISCUSSION: Research evidence supporting the effectiveness of personalized doses of nicotine replacement therapy could change current practice in a variety of healthcare settings. Given the evidence that quitting smoking at any age diminishes the risk of tobacco-related morbidity and mortality, even small increases in absolute quit rates can have a substantial population-level impact on reducing smoking-related disease, mortality rates, and associated healthcare costs. TRIAL REGISTRATION: ClinicalTrials.gov, NCT03000387 . Registered on 22 December 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zawertailo L, Hendershot CS, Tyndale RF, et al. Personalized dosing of nicotine replacement therapy versus standard dosing for the treatment of individuals with tobacco dependence: study protocol for a randomized placebo-controlled trial. Trials. 2020. PMID: 32600406. doi:10.1186/s13063-020-04532-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。